Cybin's HLP003 Phase 3 Trial Nears Full Enrollment, Surpassing 86% for MDD Treatment
HELP sits 27% above its 52-week low of $3.76.
Summary
Cybin Inc. announced that its HLP003 Phase 3 clinical trial for Major Depressive Disorder has surpassed 86% enrollment, progressing as planned towards potential commercialization.
Key Events · Product Development and Regulatory · HELP
-
Phase 3 Enrollment Update
The APPROACH Phase 3 clinical trial for HLP003, targeting Major Depressive Disorder (MDD), has surpassed 86% enrollment and is progressing as planned.
-
Breakthrough Therapy Designation
HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, potentially accelerating its development and review.
-
Strong Phase 2 Efficacy Data
Previous Phase 2 data for HLP003 demonstrated long-term efficacy, with 100% response and 71% remission rates at 12 months after two doses.
Analysis · HELP · Life Sciences
For a clinical-stage pharmaceutical company, reaching over 86% enrollment in a pivotal Phase 3 trial with Breakthrough Therapy Designation is a critical de-risking event. This progress moves HLP003 significantly closer to a potential data readout and regulatory submission, which are key milestones for the company's valuation and future. This follows a partnership announced on April 28, 2026, aimed at boosting recruitment for this trial, indicating successful execution.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1872 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HELP was trading at $4.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $3.76 to $9.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.